2018 Summer Meeting 22-25 July, Imperial College, London

Poster Sessions on Monday 23 and Tuesday 24 July
In Queen’s Tower Rooms

Presenters should stand by their poster during the Monday Poster Session (13:00-14:00) if it has an odd number. Presenters should stand by their poster during the Tuesday Poster Session (13:00-14:00) if it has an even number.

Posters must be mounted on Monday morning wherever possible and should be left in place for the duration of the conference if possible. Velcro will be provided. Please note that BAP will remove any remaining posters on Wednesday at the end of the conference and these posters cannot be returned to presenters.

Posters must be no larger than 841mm WIDE by 1189mm HIGH (A0 paper size, portrait).

Full details of the poster board size: https://www.bap.org.uk/pdfs/BAP_Poster_Size.pdf

Members of the poster review panel will view the posters on both days. Poster Prizes will be awarded at the Conference Dinner on 24th July, at the Royal Garden Hotel, Kensington.

Poster Screens
Posters will also be made available on two 46” touchscreen monitors placed around Queen’s Tower Rooms. In order to maximize the impact of your poster you are encouraged to provide a copy of your poster for display on these screens.

Please supply your poster as supplied to your printer (original, high resolution files only) by FRIDAY 29 JUNE.

Posters provided by 29 June will also be forwarded to the abstract reviewers for consideration in this year’s prizes and awards in advance of poster sessions.

Upload your poster here: https://www.dropbox.com/request/Hzz5LujU5aShiYQnMKN9

Please direct any queries to Susan Chandler by email, quoting your abstract number. susan@bap.org.uk

Group A: Compulsive Disorders (A01-A09)
Group B: Schizophrenia (B01-B15)
Group C: Developmental Disorders (C01-C07)
Group D: Applied Clinical Research (D01-D14)
Group E: Drug Dependence (E01-E16)
Group F: Cognition (F01-F25)
Group G: Immune Dysfunction (G01-G23)
Group H: Neuroimaging (H01-H23)
Group I: Affective Disorders (I01-I27)
Group J: Other (J01-J06)
Group A: Compulsive Disorders

A01
DEVELOPMENTAL TRAJECTORIES OF GOAL-DIRECTED AND HABITUAL LEARNING AND THEIR RELEVANCE FOR COMPULSIVITY
Vaghi MM, Hauser TU, Kievit RA, Moutoussis M, Shahar N, NSPN Consortium, Jones PB, Goodyer IM, Bullmore ET, Dolan RJ

A02
CHARACTERIZATION OF 8-OH-DPAT-DISRUPTED SPONTANEOUS ALTERNATION BEHAVIOUR AS AN INDUCED MODEL OF COMPULSIVE-LIKE RESPONSES.
Fitzpatrick CM, Uilitiko A, Jessen L, Andreasen JT

A03
ACTIVATION OF ANGIOTENSIN TYPE 2 RECEPTOR (AT2R) CONTRIBUTES TO FEAR MEMORY
Marvar PJ, Yu Z, Swiercz AP, Hopkins L, Krause EG, Park J

A04
EFFECTS OF MANIPULATING GONADAL HORMONES DURING ADOLESCENCE ON ANXIETY-LIKE, NOVELTY-SEEKING AND SOCIAL BEHAVIOUR IN LABORATORY RATS
Hodgson AR, Brown GR, Kulbarsh K

A05
BACLOFEN AND ANXIETY SYMPTOMS IN PATIENTS WITH ALCOHOL USE DISORDERS: STRUCTURED REVIEW
Amaro H, Sinclair JS, Baldwin DS

A06
BNC210 EFFECTS ON CBF IN ANXIETY-RELATED CORTICAL REGIONS
Macare CJ, O'Connor S, Williams SCR, O'Daly O, Perkins AM, Young AH

A07
INFLAMMATORY CYTOKINES IN OBSESSIVE-COMPULSIVE DISORDER: A SYSTEMATIC REVIEW
Tofani T, Pallanti S, Hou R, Baldwin DS

A08
COMPUTATIONS UNDERLYING ATTENTIONAL BIAS TOWARD THREAT
Wise T, Michely J, Dayan P, Dolan RJ
This will also be a Short Oral presentation on Tuesday afternoon

A09
INDUCED ANXIETY MAKES TIME PASS QUICKER
Sarigiannidis IS, Grillon CG, Ernst ME, Roiser JR, Robinson OR
Group B: Schizophrenia

B01
THE EFFECT OF CANNABIDIOL ON THE GLUTAMATE SYSTEM: A SYSTEMATIC REVIEW
Jones APM, Bloomfield MAP, Freeman TP, Hindocha C

B02
WHAT BIOLOGICAL AND SELF-REPORT FACTORS PREDICT ACUTE PSYCHOSIS-LIKE SYMPTOMS AND DRUG DEPENDENCY IN YOUNG CANNABIS USERS?
Hindocha C, Curran HV, Morgan CJA, ShaBan NDC, DAS RK, Freeman TP

B03
PROVISIONAL SUPPORTING EVIDENCE FOR THE CANNABIS DISCONTINUATION HYPOTHESIS - PRELIMINARY ANALYSIS OF THE INTERNATIONAL CANNABIS EXPERIENCES SURVEY 2018
Sami MB, Rai A, Bhattacharyya S

B04
USING PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELLS TO UNDERSTAND THE MECHANISMS UNDERLYING THE BENEFICIAL EFFECTS OF ESTROGENS IN SCHIZOPHRENIA
Srivastava DP, Deans PJM, Perfect L, Dutan-Polit L, Shum C, Conforti M, Duarte RR, Powell T, Bhattacharyya S, Price J

B05
LONGITUDINAL STUDY INVESTIGATING THE ASSOCIATION BETWEEN BDNF LEVELS AND TREATMENT RESPONSE IN FIRST-EPISODE PSYCHOSIS

B06
A NOVEL GENETIC INSTRUMENT FOR LIFETIME SMOKING INDICATES THAT SMOKING IS A CAUSAL RISK FACTOR FOR DEPRESSION AND SCHIZOPHRENIA
Wootton RE, Munafò MR

B07
THE EFFECT OF KETAMINE ON PSYCHOPATHOLOGY AND IMPLICATIONS FOR UNDERSTANDING SCHIZOPHRENIA: A META-ANALYSIS
This will also be a Short Oral presentation on Tuesday afternoon

B08
DNA METHYLATION CHANGES OF GRIN1 AND GRIN2B NMDAR PROMOTE REGION IN RATS REARED UNDER ISOLATION
Loureiro CM, Fachim HA, Corsi-Zuelli FMG, Shuhama R, Joca SRL, Menezes PR, Del-Ben CM, Dalton CF, Reynolds GP, Louzada-Junior P

B09
PROTEIN TRANSLATION IN THE PSYCHIATRIC-RELEVANT CYFIP1 KO MOUSE MODEL: UNALTEDER ACTIVITY OF UPSTREAM TRANSLATION PATHWAYS BUT IMPACT ON DOWNSTREAM FMRP TARGET ARC AND CYFIP1 ITSELF
Trent S, Meeson N, Best C, Hall J
ROLE OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN PSYCHOSIS AND DOPAMINE SENSITIZATION: A PROTEOMICS STUDY OF THE EFFECTS OF CHRONIC METHAMPHETAMINE IN BDNF VAL66MET MICE
van den Buuse M, Greening DW, Notaras MJ

COMMUNICATION BREAKDOWN AND DECOUPLING OF PRELIMBIC CORTEX-VENTRAL HIPPOCAMPUS LINKAGE IN THE SUB-CHRONIC PHENCYCLIDINE SCHIZOPHRENIA MODEL: HOW LOCAL FIELD POTENTIAL PHASE UNDERPINS INTERNAL AND INTRA-REGIONAL PATHOLOGY
Netherwood BR, Gigg J, Montemurro M, Doostar N, Davy O

GABAERGIC, NOT SEROTONERGIC, ALTERATIONS APPEAR TO UNDERLIE REDUCED EFFICACY OF 5-HT6 RECEPTOR ANTAGONISTS IN A DUAL-HIT NEURODEVELOPMENTAL MODEL FOR SCHIZOPHRENIA
King MV, Newton-Mann E, Dawe-Lane E, Evans C, Fowler M

NON-SPATIAL WORKING MEMORY DEFICITS IN THE SUB-CHRONIC PHENCYCLIDINE (PCP) MODEL FOR SCHIZOPHRENIA ASSESSED IN THE ODOUR SPAN TASK
Burgess MA, Podda G, Metcalf TO, Aarons T, Grayson B, Neill JC

SPATIAL WORKING MEMORY DEFICITS IN THE SUB-CHRONIC PHENCYCLIDINE (PCP) MODEL FOR SCHIZOPHRENIA ASSESSED IN THE RADIAL MAZE TASK
Farrow LE, Burgess M, Podda G, Munni S, Grayson B, Neill JC

THE NEURAL BASIS OF WORKING MEMORY IMPAIRMENT IN PSYCHOSIS AND ITS RELATIONSHIP TO NEGATIVE SYMPTOMS: AN FMRI STUDY IN FIRST EPISODE PATIENTS
Pepper F, O'Daly O, Kotoula V, Jauhar S, Howes OD
Group C: Developmental Disorders

C01
THE EFFECT OF POLY (I:C)-INDUCED IMMUNE ACTIVATION ON MOUSE OFFSPRING: A SYSTEMATIC REVIEW AND META-ANALYSIS
Kelly JP, Concannon J, Costigan A, Gibling A, McInerney A, Olayiwola O, Philip A

C02
NEUREXIN-1A (NRNX1A) HETEROZYGOsITY INDUCES HYPOFRONTALITY AND DEFICITS IN COGNITIVE FLEXIBILITY
Hughes RB, Whittingham-Dowd J, Bristow G, Clapcote S, Broughton S, Dawson N

C03
NEUREXIN 1 (NRXN1) HETEROZYGOSITY IMPACTS ON GUT ARCHITECTURE AND INDUCES GUT DYSBIOSIS
Whittingham-Dowd JK, Hughes R, Bristow G, McMaster E, Clapcote SJ, Rigby RJ, Dawson N

C04
ASSESSING EFFECTS OF ATOMOXETINE AND METHYLPHENIDATE ON ATTENTION USING 5-CHOICE SERIAL REACTION TIME TASK (5-CSRTT)

C05
A NEUROCOMPUTATIONAL ACCOUNT OF REWARD AND NOVELTY PROCESSING AND EFFECTS OF PSYCHOSTIMULANTS IN ATTENTION DEFICIT HYPERACTIVITY DISORDER
Sethi A, Voon V, Critchley HD, Cercignani M, Harrison NA
This will also be a Short Oral presentation on Tuesday afternoon

C06
METHYLPHENIDATE AND ATOMOXETINE NORMALISE FRONTO-PARIETAL ACTIVATION IN ADHD DURING SUSTAINED ATTENTION
Kowalczyk OS, Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer M, Simmons A, Rubia K

C07
MATERNAL IMMUNE ACTIVATION IS ASSOCIATED WITH REDUCED PLACENTAL GROWTH AND ALTERED PLACENTAL GENE EXPRESSION IN A RAT MODEL FOR SCHIZOPHRENIA
Kowash HM, Yinou X, Potter HG, Munni STM, Hager R, Neill JC, Glazier JD
Group D: Applied Clinical Research

D01
THE USE OF DEPOT/LONG-ACTING INJECTABLE ANTIPSYCHOTIC MEDICATION FOR RELAPSE PREVENTION IN SCHIZOPHRENIA IN THE UK
Barnes TRE, Bari MJ, Craig TKJ, Paton C

D02
IMPACTS OF CAFFEINE INTAKE UPON CLOzapine USERS
Patel KR, Sain K

D03
IS THERE REBOUND PSYCHOSIS ON ANTIPSYCHOTIC WITHDRAWAL IN SCHIZOPHRENIA?
Taylor MJ, Yim S

D04
A RETROSPECTIVE, MIRROR-IMAGE STUDY OF THE EFFECTIVENESS OF ARIPIPRAZOLE LONG ACTING INJECTION ON HOSPITALIZATION RATES AND HOSPITAL IN-PATIENT STAY FOLLOWING INITIATION OF ARIPIPRAZOLE LONG ACTING INJECTION
Secchi A

D05
A COMPLETED AUDIT CYCLE ON PHYSICAL HEALTH MONITORING OF PATIENTS ON ANTI-PSYCHOTICS
Chinnasamy M, Wilkinson C, De Ivey R, Albarri M, Wilson S

D06
CELECOXIB PLUS STANDARD CARE FOR PEOPLE WITH SCHIZOPHRENIA: A COCHRANE REVIEW
Kotecha AN, Upthegrove R

D07
THE APPLICATION OF N-OF-1 TREATMENT TRIALS IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Marwick KF, Stevenson AJ, Davies C, Lawrie SM

D08
BLUNTED AFFECT AND SUICIDE IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Grigoriou MG, Bortolotti LB, Upthegrove RU

D09
AFFECTIVE SYMPTOMS PREDICT THE METABOLIC SYNDROME AND SYMPTOM SEVERITY IN PATIENTS WITH PSYCHOSIS

D10
REDUCING RISKS ASSOCIATED WITH VITAMIN D DEFICIENCY IN AN OLDER ADULT PSYCHIATRIC INPATIENT WARD
Alalade A, Morris S, Littlewood C
D11
THE DOCUMENTATION OF ALCOHOL HISTORIES IN A COHORT OF DEMENTIA PATIENTS

D12
PERSONAL EXPERIENCES OF THE EFFECTS OF BARIATRIC SURGERY ON PHYSICAL AND MENTAL WELLBEING IN SEVERE MENTAL ILLNESS: A QUALITATIVE STUDY
Tomlinson A, Every-Palmer S, Ghandi S, Huthwaite M, Stubbs R, Romans SE

D13
GLUCOSE AND LIPID ALTERATIONS IN ANTIPSYCHOTIC NAÏVE FIRST EPISODE PSYCHOSIS: EVIDENCE OF INTRINSIC CARDIOMETABOLIC RISK?
McCutcheon R, Beck K, Stubbs B, Jauhar S, Howes OD, Pillinger T

D14
WHAT LEADS TO PSYCHOSIS TRANSITION? A META-ANALYSIS OF RISK AND PROTECTIVE FACTORS IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS
Oliver D, Reilly T, Baccaredda O, Petros N, Fasar-Poli P
Group E: Drug Dependence

E01
INVESTIGATING THE EFFECTIVENESS OF NOVEL CALORIE/UNIT INDICATOR BEER MATS USING A GROUP TESTING PROCEDURE

E02
RISKY DECISION-MAKING INCREASES STRESS-INDUCED ALCOHOL CONSUMPTION IN SOCIAL DRINKERS
Clay JM, Parker MO

E03
EXAMINING THE TIME COURSE OF ETHANOL WITHDRAWAL AND CORRELATIONS WITH BASELINE IMPULSIVITY
Collins DM, Mitchell SH, Finn DA

E04
RELATIONSHIP BETWEEN REWARD ANTICIPATION AND IMPULSIVITY IN ALCOHOL AND POLYDRUG ADDICTION: AN FMRI STUDY

E05
INFLUENCE OF GLP-1 ANALOGUE, EXENATIDE, ON FOOD AND ALCOHOL CUE REACTIVITY, AND APPROACH BIAS IN HUMAN OBESITY, EX-SMOKERS AND ABSTINENT ALCOHOL DEPENDENCE

E06
MONETARY REWARD PROCESSING AND FOOD ADDICTION IN OBESE WOMEN AND IMPACT OF GASTRIC BYPASS SURGERY
Brian EJG, Chhina N, Nestor LJ, Hannan R, Nutt DJ, Lingford-Hughes AR, Goldstone AP

E07
VALUE-BASED DECISION-MAKING OF CIGARETTES AND NON-DRUG REWARDS IN DEPENDENT AND OCCASIONAL CIGARETTE SMOKERS: AN FMRI STUDY
Lawn WM, Freeman TP, Benattayallah A, Bisby JA, Mitchener L, Curran HV, Dodds C, Morgan CJA

E08
INFLUENCE OF GLP-1 ANALOGUE, EXENATIDE, ON CIGARETTE CUE REACTIVITY AND CRAVING IN EX-SMOKERS AND ABSTINENT ALCOHOL-DEPENDENT CURRENT SMOKERS

E09
EXAMINING REINFORCEMENT LEARNING ACROSS TWO DISORDERS OF COMPELSIVITY USING BAYESIAN HIERARCHICAL MODELLING
Kanen JW, Ersche KD, Robbins TW, Cardinal RN
E10 INVESTIGATION OF THE REINFORCING EFFECT OF BARBITURATES AND BENZODIAZEPINES IN RATS TRAINED TO SELF-ADMINISTER HEROIN
Smith S, Keogh E, Holland S, Slade J, Heal D

E11 MODULATION OF NATURALISTIC MALADAPTIVE MEMORIES USING BEHAVIOURAL AND PHARMACOLOGICAL RECONSOLIDATION-INTERFERING STRATEGIES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL AND ‘SUB-CLINICAL’ STUDIES
Walsh KH, Das RK, Saladin ME, Kamboj SK

E12 CHARACTERISTICS OF OPIATE DEPENDENT PATIENTS ON STABLE, “LOW DOSE” METHADONE
Zhou K, Turton S, Golob D, Moore A, Lingford-Hughes A

E13 CHARACTERISTICS OF OPIATE DEPENDENT PATIENTS RECEIVING ‘HIGH’ AND ‘LOW’ DOSE METHADONE
Perinpathasan K, Turton S, Golob D, Moore A, Lingford-Hughes A

E14 GENETIC VARIATION IN DOPAMINE AND OPIOID RECEPTOR GENES DOES NOT PREDICT STRIATAL BOLD RESPONSE TO REWARD ANTICIPATION IN SUBSTANCE DEPENDENCE

E15 SYNTHETIC CANNABINOID USE IS ASSOCIATED WITH SIGNIFICANTLY WORSE OUTCOMES COMPARED TO NATURAL CANNABIS: A MENTAL HEALTH ELECTRONIC CASE REGISTER STUDY

E16 ALAMA-NIGHTLIFE – ASSESSING THE REPRESENTATIVENESS OF RECRUITING ONLINE FOR A NIGHTLIFE AND DRUG USE SURVEY USING Targeted SOCIAL MEDIA ADVERTISING
Waldron J, Grabski M, Freeman TP, Curran HV
Group F: Cognition

F01
QUALITY OF MOTHER-INFANT INTERACTION IS ASSOCIATED WITH PERFORMANCE ON THE BAYLEY SCALE OF INFANT DEVELOPMENT

F02
A NOVEL METHOD FOR MODIFYING FRONTOPARIETAL NETWORK PLASTICITY AND ITS EFFECTS ON DECISION-MAKING
This will also be a Short Oral presentation on Tuesday afternoon

F03
NEUROCOGNITIVE CORRELATES OF WORKING MEMORY IN POSTPARTUM PSYCHOSIS
Kowalczyk OS, Pauls A, Dazzan P, Mehta MA

F04
A NOVEL RAPID SERIAL VISUAL PRESENTATION TASK FOR INVESTIGATING ATTENTION IN MICE
Brennan LJ, Goikolea A, Sorenson O, Robinson E

F05
THE COGNITIVE AND NEURAL MECHANISMS OF MOTIVATION TO EXERT COGNITIVE EFFORT

F06
ADAPTIVE LEARNING FROM ENVIRONMENTAL CONTINGENCIES IN EATING-DISORDER RISK GROUPS
Pike AC, Pulcu E, Sharpley AL, Park RJ, Cowen PJ, Browning M

F07
INTEGRATION OF POST-DECISION EVIDENCE AND CONFIDENCE JUDGEMENTS IN DEPRESSION
Payne MEM, Rollwage M, Fleming SM, Roiser JP

F08
COMPUTATIONAL NEUROPHARMACOLOGY OF IMPULSIVE PREMATURE RESPONDING IN HUMANS
This will also be a Short Oral presentation on Tuesday afternoon

F09
THE EFFECTS OF COMT AND COMT INHIBITION ON EMOTIONAL PROCESSING

F10
THE ROLE OF THE ADENOSINE SYSTEM IN HUMAN COGNITION: PILOT FINDINGS USING ISTRADEFYLLINE
Hook RW, Isobe M, Christmas D, Ioannidis K, Chamberlain SR
ACUTE CITAPRAM ADMINISTRATION REDUCES INFORMATION SAMPLING IN HEALTHY VOLUNTEERS
Livermore JJA, Holmes C, Brittain J, Cutler J, Moga G, Campbell-Meiklejohn D
This will also be a Short Oral presentation on Tuesday afternoon

THE OFF-PRESCRIPTION USE OF MODAFINIL: AN ONLINE SURVEY OF PERCEIVED RISKS AND BENEFITS
Teodorini RD, Rycroft N, Smith-Spark JH

GRIN2B PROMOTER METHYLATION DEFICITS IN EARLY SCHIZOPHRENIA AND CORRELATION WITH INTELLIGENCE QUOTIENT (IQ) PERFORMANCE

DIFFERENTIAL EFFECTS OF MGLU5 POSITIVE ALLOSTERIC MODULATORS ON COGNITION AND PREFRONTAL CORTEX SIGNALLING IN THE SUB-CHRONIC PCP ANIMAL MODEL
Grayson B, Iacovelli L, Podda G, Idris NF, Munni STM, Di Cicco G, Ngomba RT, Neill JC

SEROTONIN TRANSPORTER OVEREXPRESSION IS ASSOCIATED WITH IMPAIRED BEHAVIOURAL FLEXIBILITY ON CONTINGENCY DEGRADATION/REVERSAL TASK IN MICE
Bien Z, Murphy RA, Baker AG

NEURODEVELOPMENTAL CHANGES AND MATERNAL CARE BEHAVIOUR IN A RAT MODEL FOR SCHIZOPHRENIA
Potter HG, Wang AT, Munni STM, Kowash HM, Glazier JD, Neill JC, Hager R

DEFICITS IN WORKING MEMORY AND DECREASED PREFRONTAL PARVALBUMIN EXPRESSION IN THE 16P11.2 DUPLICATION MOUSE MODEL WITH RELEVANCE TO SCHIZOPHRENIA

16P11.2 DUPLICATION MICE SHOW ACQUISITION DEFICITS IN THE TOUCHSCREEN CONTINUOUS PERFORMANCE TASK
Thomson DM, Mitchell E, Openshaw RL, Bristow GC, Dawson N, Morris BM, Pratt JA

EXAMINATION OF HOME-CAGE ACTIVITY IN A MOUSE MODEL OF 16P11.2 DUPLICATION
Mitchell EJ, Thomson DM, Bristow GC, Openshaw RL, Dawson N, Morris BJ, Pratt JA
DISRUPTION OF THE ZDHHC9 INTELLECTUAL DISABILITY GENE LEADS TO BEHAVIOURAL ABNORMALITIES IN A MOUSE MODEL
Kouskou M, Thomson DM, Brett RR, Wheeler L, Pratt JA, Chamberlain LH

THE EFFECTS OF CANNABIDIOL ON REWARD PROCESSING: A SYSTEMATIC REVIEW
Yim LL, Freeman T, Hindocha C, Bloomfield MAP

THE ROLE OF THE CANNABINOID SYSTEM IN MEMORY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFECTS OF CANNABINOID RECEPTOR 1 RECEPTOR AGONISTS AND ANTAGONISTS ON MEMORY
Borgan F, Beck KB, McCutcheon RM, Vernon AV, Veronese MV
Faith Borgan was awarded the 2018 Hannah Steinberg Bursary

THE EFFECTS OF CANNABIDIOL ON EMOTIONAL PROCESSING AND ANXIETY: A SYSTEMATIC REVIEW
Yamamori Y, Freeman TP, Hindocha C, Bloomfield MAP

ASSESSING A NOVEL SYSTEM FOR HEAD-FIXATION IN AWAKE, BEHAVING MICE PERFORMING A CUED GOAL LOCALISATION TASK
Stuart SA, Mellor JR

EFFECTS OF CONVENTIONAL ADHD MEDICATIONS ON IMPULSIVE ACTION IN THE MOUSE 5-CHOICE SERIAL REACTION TIME TASK
Fitzpatrick CM, Andreasen JT
Group G: Immune Dysfunction

G01
IS PSYCHOSIS A MULTI-SYSTEM DISORDER? CONSIDERING IMMUNE, CARDIOMETABOLIC, AND ENDOCRINE FUNCTION IN FIRST EPISODE PSYCHOSIS AND COMPARISON WITH CENTRAL NERVOUS SYSTEM ALTERATIONS
McCutcheon R, D'Ambrosio E, Howes OD, Pillinger T

G02
METABOLIC-INFLAMMATORY STATUS AS PREDICTOR OF CLINICAL OUTCOME AT 1-YEAR FOLLOW-UP IN PATIENTS WITH FIRST EPISODE PSYCHOSIS

G03
EXPLORING THE RELATIONSHIP BETWEEN INFLAMMATORY BIOMARKERS AND DEPRESSION IN FIRST EPISODE PSYCHOSIS IN A 1-YEAR LONGITUDINAL STUDY

G04
HOW TREATMENT AFFECTS PERIPHERAL INFLAMMATORY MARKERS IN MOOD DISORDERS? A SYSTEMATIC REVIEW
Wijayaweera SS, Hou R

G05
TREATMENT-RESISTANT DEPRESSION: A POSSIBLE 'INFLAMMATORY SUBTYPE' OF DEPRESSIVE DISORDER
Strawbridge R, Young AH, Cleare AJ

G06
INFLAMMATION POPULATION SUB-GROUPS BASED ON LONGITUDINAL CRP ASSESSMENTS AS PREDICTORS OF DEPRESSION: FINDINGS FROM THE ALSPAC BIRTH COHORT
Osimo EF, Stochl J, Khandaker GK

G07
CHARACTERISTICS OF YOUNG ADULTS WITH DEPRESSION AND LOW-GRADE INFLAMMATION IN THE ALSPAC BIRTH COHORT
Oltean BP, Lewis G, Jones PB, Khandaker GM

G08
THE SYNERGISTIC EFFECT OF MATERNAL IMMUNE ACTIVATION (MIA) AND ADOLESCENT THC TREATMENT IN ADULT OFFSPRING: TOWARDS A 2HIT MODEL FOR SCHIZOPHRENIA
Podda G, Cadinu D, Munni S, Grayson B, Neill JC

G09
CHILDHOOD MALTREATMENT AND INFLAMMATION IN FIRST-EPISODE PSYCHOSIS AND UNAFFECTED SIBLINGS: RESULTS FROM THE STREAM STUDY IN BRAZIL
G10
PROLONGED PERIODS OF SOCIAL ISOLATION FROM WEANING IS MARKED BY AN IMPAIRED BLOOD-BRAIN ANTI-INFLAMMATORY RESPONSE

G11
INFLAMMATORY PATHWAYS IN DEPRESSION AND OBESITY

G12
P2X7R AS BIOMARKER OF TREATMENT RESPONSE IN DEPRESSED PATIENTS

G13
SERUM LEVELS OF ADRENOCORTICOTROPIC HORMONE AND THYROID STIMULATING HORMONE ARE ASSOCIATED WITH SUICIDAL THOUGHTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Hou RH, Li XR, Baldwin DS, Sun XL

G14
DIFFERENCES IN CORTISOL LEVELS USING SALIVA, HAIR AND FINGERNAIL SPECIMENS IN DEPRESSIVE AND HEALTHY PEOPLE

G15
MARKERS OF CENTRAL INFLAMMATION IN MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Enache ED, Mondelli MV, Pariante PC

G16
THE ROLE OF BASELINE PERIPHERAL CORTISOL LEVELS IN THE EFFICACY OF ANTIGLUCOCORTICOID TREATMENT IN PATIENTS WITH MOOD DISORDERS: A META-ANALYSIS
Lombardo G, Enache D, Gianotti L, Pariante C, Mondelli V

G17
THE EFFECT OF POLYMORPHISMS RELATED TO HPA AXIS ON TREATMENT RESPONSES: A SYSTEMATIC REVIEW
Kuter BK, Cleare AJC, Juruena MFJ

G18
CAN THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS FUNCTION AS A BIOMARKER FOR DEPRESSION IN PATIENTS WITH A HISTORY OF EARLY LIFE STRESS? – A SYSTEMATIC REVIEW
Bourne M, Cleare AJ, Juruena MF
G19
POST-TRAUMATIC STRESS SYMPTOMS FOLLOWING CHILDHOOD SEPSIS: THE IMPACT OF INFLAMMATION AND CORTICOSTEROIDS.
Corbet Burcher G, Caspani G, Cooper M, Pierce C, Als L, Garralda E, Nadel S

G20
CHRONIC HALOPERIDOL TREATMENT DRIVES CENTRAL MICROGLIAL ACTIVATION IN RATS EXPOSED PRENATALLY TO MATERNAL IMMUNE ACTIVATION – DO ANTIPSYCHOTICS INFLAME THE BRAIN?
Vernon AC, Cotel MC, Polacek R, Lenartowicz E, Natesan S

G21
SCHIZOPHRENIA RISK GENE CYFIP1 IS REQUIRED FOR MICROGLIAL REGULATION OF NEURONAL NUMBER IN THE POSTNATAL HIPPOCAMPUS
Haan N, Carter J, Westacott LJ, Hall J, Wilkinson LS

G22
DIFFERENTIAL EFFECT OF AEA AND 2-AG IN INFLAMMATION
Zajkowska ZE, Russell A, Hepgul N, Borsini A, Nikkheslat N, Forton D, Agarwal K, Mondelli V, Zunszain PA, Pariante CM

G23
A LONGITUDINAL INVESTIGATION OF THE NEURODEVELOPMENTAL IMPACT OF MATERNAL IMMUNE ACTIVATION ON PARVALBUMIN INTERNEURONS IN THE PREFRONTAL CORTEX AND DORSAL HIPPOCAMPUS IN THE RAT
Munni STM, Grayson B, Podda G, Yeo ZH, Neill JC, Harte MK
Group H: Neuroimaging

H01
TRAJECTORIES AND MILESTONES OF CORTICAL AND SUBCORTICAL DEVELOPMENT OF THE MARMOSET BRAIN FROM INFANCY TO ADULTHOOD

H02
SCHIZOPHRENIA-RELEVANT ALTERATIONS IN CEREBRAL METABOLISM AND NEUROTRANSMITTER SYSTEM DYSFUNCTION IN A MOUSE MODEL OF 16P11.2 DUPLICATION
Bristow GC, Thomson DM, Mitchell EJ, Openshaw RL, Pratt JA, Morris BJ, Dawson N
This will also be a Short Oral presentation on Tuesday afternoon

H03
LOW LEVELS OF VITAMIN D ARE ASSOCIATED WITH REDUCED CORTICAL THICKNESS AND SURFACE AREA IN FRONTAL, TEMPORAL AND OCCIPITAL REGIONS OF PATIENTS AT THEIR FIRST-EPISEDE PSYCHOSIS
Ciufolini SC, Lally JL, Stubbs BS, Smith SS, DiForti MD, Dazzan PD, Howes OH, Murray RM, Gaughran FG

H04
REMISSION FROM ANTIPSYCHOTIC TREATMENT RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS

H05
THE RELATIONSHIP BETWEEN CORTICAL GLUTAMATE AND STRIATAL DOPAMINE FUNCTION IN PSYCHOSIS: A MULTI-MODAL PET AND MRS IMAGING STUDY IN FIRST EPISODE PSYCHOSIS

H06
HEARING NON-EXISTENT VOICES: A RESTING STATE FMRI STUDY ON SCHIZOPHRENIA WITH AUDITORY VERBAL HALLUCINATIONS
Chu KM, Upthegrove R, Mallikarjun PK

H07
INNER SPEECH MODELS OF AUDITORY VERBAL HALLUCINATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Barber LB, Upthegrove RU, Reniers RR

H08
THE EFFECTS OF CHILDHOOD TRAUMA ON BRAIN STRUCTURE AND FUNCTION IN PEOPLE WITH PSYCHOTIC EXPERIENCES: A SYSTEMATIC REVIEW OF NEUROIMAGING STUDIES
Modaffar M, Bloomfield MA
H09 INCREASED CEREBRAL BLOOD FLOW AFTER SINGLE DOSE OF ANTIPSYCHOTICS IN HEALTHY VOLUNTEERS DEPENDS ON DOPAMINE D2 RECEPTOR DENSITY PROFILES

H10 MESOLIMBIC DOPAMINE FUNCTION AND SALIENCE NETWORK CONNECTIVITY: AN INTEGRATIVE PET AND MR STUDY

H11 ABNORMAL FRONTOSTRIATAL CONNECTIVITY IN PSYCHIATRIC DISORDERS: A REVIEW
Walker HR, Freeman TP, Bloomfield MAP

H12 INVESTIGATING THE EFFECTS OF ACUTE \( \Delta^9 \)-TETRAHYDROCANNABINOL ON CEREBRAL BLOOD FLOW – AN ARTERIAL SPIN LABELLING STUDY
Ogunbiyi MO, Lees RL, Petrilli KP, Hindocha CH, Howes OH, Freeman TF, Hales PH, Curran HVC, Bloomfield MB

H13 FUNCTIONAL MAGNETIC RESONANCE SPECTROSCOPY IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR AFFECTIVE DISORDER: GLUTAMATE DYNAMICS IN THE ANTERIOR CINGULATE CORTEX DURING A WORKING MEMORY TASK
Jelen LA, King S, Lythgoe DJ, Stone JM
*This will also be a Short Oral presentation on Tuesday afternoon*

H14 CAN THE LOCUS COERULEUS ACTIVITY BE MEASURED BY MAGNETIC RESONANCE IMAGING? A FEASIBILITY STUDY
Hou R, Ollington R, Lewis E, Everitt C, Holmes C, Darekar A

H15 THE ROLE OF ANTERIOR CINGULATE CORTEX IN PREDICTING TREATMENT RESPONSE IN DEPRESSION
Godlewska BR, Browning M, Norbury R, Igoumenou A, Cowen PJ, Harmer CJ

H16 SUBGENUAL CINGULATE ACTIVATION AND THE FINGER OF BLAME: INDIVIDUAL DIFFERENCES AND DEPRESSION VULNERABILITY
Zahn R, Lythe K, Gethin JE, Workman CI, LambonRalph MA, Deakin JFW, Moll J

H17 EFFECTS OF SEROTONIN AND DOPAMINE DEPLETION ON NEURAL CORRELATES OF EMOTIONAL EXPRESSION PREDICTION
Frey AL, McCabe C
H18
FMRI STUDY OF IMPULSE CONTROL IN GO/NO-GO TASK – NEURAL CORRELATES IN DISORDERED GAMBLING

H19
ALTERED CORTICAL CANNABINOID 1 RECEPTORS AND FUNCTIONAL CORRELATES OF MEMORY IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET-FMRI STUDY
Borgan F, O'Daly OD, Veronese MV, Howes OH

H20
Borgan F, Laurikainen HK, Veronese MV, Marques TM, Dahoun TD, Rogdaki MR, Hietala JH, Howes OH

H21
ENDOGENOUS OPIOID RELEASE MEASURED IN THE HUMAN BRAIN: A POSITRON EMISSION TOMOGRAPHIC STUDY WITH [11C] CARFENTANIL AND SODIUM ACETATE CHALLENGE

H22
COMPARING SPRAY VS NEBULIZED OXYTOCIN MODULATION OF BRAINWIDE RESTING-STATE FUNCTIONAL CONNECTIVITY: A PERIPHERALLY CONTROLLED PHARMACO-MRI STUDY
Martins D, Dipasquale O, Zelaya F, Mazibuko N, O'Daly O, O'Muircheartaigh J, Maltezos S, Schuschnig U, Williams S, Paloyelis Y

H23
OXYTOCIN MODULATION OF RESTING STATE REGIONAL CEREBRAL BLOOD FLOW (RCBF): COMPARING THE EFFECTS OF INTRANASAL AND INTRAVENOUS METHODS OF ADMINISTRATION
Paloyelis Y, Zelaya F, Mazibuko N, Maltezos S, Schuschnig U, Williams S

This will also be a Short Oral presentation on Tuesday afternoon
Group I: Affective Disorders

I01 RESCUE OF CYTOKINES INDUCED REDUCTION OF HUMAN NEUROGENESIS AND INCREASE IN APOPTOSIS BY OMEGA-3 FATTY ACIDS
Borsini A, Pariante CM, Su K, Zunszain P

I02 ACUTE KETAMINE TREATMENT REVERSES STRESS-INDUCED SOCIAL AVOIDANCE AND MODULATES INFLAMMATORY SIGNALLING.
Sokolowska E, Burke T, Dunphy-Doherty F, McDonnell CW, Prenderville JA, Bianchi M

I03 EFFECTS OF ANTIDEPRESSANT DRUGS ON PLASMA MICROTUBULAR PROTEINS IN “HEALTHY” SPRAGUE DAWLEY AND “DEPRESSED” WISTAR KYOTO RATS
McDonnell CW, Prenderville JA, Rouine J, Burke T, Dunphy-Doherty F, Lobato JP, Gill M, Bianchi M

I04 INCREASED MYELINATION AND SYNAPTIC PROTEINS IN MICE EXPOSED TO INTERMITTENT (R,S)-KETAMINE: LINKING MAGNETIC RESONANCE IMAGING FINDINGS TO CELLULAR PATHOLOGY
Vernon AC, Cheserts RA, Cooper JD, Stone JM
This will also be a Short Oral presentation on Tuesday afternoon

I05 FLUOXETINE PRE-EXPOSURE DECREASES COCAINE AND SUCROSE PREFERENCE IN FEMALE MICE
Iniguez SD, Flores-Ramirez FJ

I06 PSYCHOPHARMACOLOGICAL EVALUATION OF A RODENT PROBABILISTIC REVERSAL LEARNING TASK
Wilkinson MP, Mellor JR, Robinson ESJ

I07 FURTHER VALIDATION OF THE REWARD-BASED JUDGEMENT BIAS TASK: IMMEDIATE POSITIVE BIASES ARE INDUCED BY DRUGS WITH KNOWN CLINICAL RAPID ONSET ANTIDEPRESSANT ACTION
Hales CA, Bartlett J, Hengerer B, Robinson ESJ
This will also be a Short Oral presentation on Tuesday afternoon

I08 CAN THE ‘BURROWING’ TEST PROVIDE MORE INSIGHT INTO PATHOPHYSIOLOGY OF DEPRESSION COMPARED TO TRADITIONAL TESTS?
Nabi L, Borbely E, Hajna Z, Tekus V, Fernandes M, Pinter E, Helyes Z, Keeble J

I09 INVESTIGATING THE EFFECTS OF SEX ON DEPRESSION-RELATED BEHAVIOUR EVOKE BY KAPPA OPIOID RECEPTOR ACTIVATION IN THE FORCED SWIM TEST.
Lalji HM, Sadler AM, Bailey CP, Bailey SJ
I10  
EFFECTS OF KAPPA OPIOID RECEPTOR AGONISTS AND ACUTE STRESS ON BRAIN REGIONS IMPLICATED IN THE RESPONSE TO STRESS AND DRUGS OF ABUSE  
Ma Q, Wonnacott S, Bailey SJ, Bailey CP

I11  
THE SYNERGISTIC PHARMACOLOGICAL INTERACTION OF COMPOUNDS PRESENT IN AYAHUASCA: A SYSTEMATIC REVIEW  
Ruffell SGD, Netzband ND, Young AH, Juruena MF

I12  
TRUE COLOURS MONITORING IN TREATMENT RESISTANT DEPRESSION: A QUALITATIVE STUDY OF PATIENTS’ PERSPECTIVES  

I13  
VALIDATING AN OBJECTIVE MEASURE OF MOTIVATION FOR REWARD USING A JOYSTICK-OPERATED RUNWAY TASK  
Slaney C, Houghton CJ, Penton-Voak I, Munafö M, Robinson ESJ

I14  
EVALUATING THE ANXIOLYTIC POTENTIAL OF AMILORIDE IN THE 7.5% CARBON DIOXIDE EXPERIMENTAL MODEL OF ANXIETY  
Parker R, Mahood F, Taylor ANW, Mills S, Hou R, Baldwin DS, Garner M

I15  
EFFECTICITY OF AFFECTIVE BIAS MODIFICATION VIA SMARTPHONES IN A LARGE POPULATION SAMPLE  
Chelliah A, Robinson OJ  
*This will also be a Short Oral presentation on Tuesday afternoon*

I16  
EMOTION PROCESSING BIASES OF MENTAL IMAGERY IN MONOZYGOTIC TWINS WITH BIPOLAR DISORDER OR UNIPOLAR DEPRESSION.  
Taylor P, Meluken I, Miskowiak K, DiSimplicio M

I17  
AUTOBIOGRAPHICAL RECALL BEFORE VS AFTER PSILOCYBIN THERAPY FOR TREATMENT RESISTANT DEPRESSION  
Porffy LA, Stroud JB, Oliver DAP, Ashton P, Lily Fitzgerald L, Freeman TP, Carhart-Harris RL

I18  
ACUTE 5-HT4 RECEPTOR AGONISM ENHANCES LEARNING, MEMORY AND REWARD SENSITIVITY IN HEALTHY VOLUNTEERS  
Murphy SM, Wright L, Browning M, Cowen PJ, Harmer CJ

I19  
MOOD INSTABILITY AND REWARD PROCESSING: DAILY REMOTE MONITORING AS A MODERN PHENOTYPING TOOL FOR BIPOLAR DISORDER.  
I20
REWARD AND MOTIVATION BIASES IN SELF-HARM
Amaralingam J, Sen K, Di Simplicio M

I21
THE FAKE IQ TEST: A NOVEL, DIRECT MEASURE OF SELF-PERCEPTION IN MAJOR DEPRESSION
Marwood L, Wise T, Patrick F, Cleare A, Perkins A

I22
EFFECT OF LURASIDONE ON COGNITION IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
Tocco M, Burdick KE, Goldman R, Deng L, Loebel A

I23
SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
Goldman R, Tocco M, Pikalov A, Deng L, Loebel A

I24
EFFECTIVENESS OF LONG-TERM TREATMENT WITH LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
Goldman R, Tocco M, Pikalov A, Deng L, Loebel L

I25
REVIEW OF PRESCRIBING AND MONITORING GUIDELINES FOR FIRST AND SECOND LINE PHARMACOLOGICAL AUGMENTATION THERAPIES IN TREATMENT RESISTANT DEPRESSION
Oprea E, Marwood L, DeAngel V, Valentini B, Mather S, Taylor R, Cleare A

I26
MIGRATION AS A RISK FACTOR FOR DEVELOPING DEPRESSION: A SYSTEMATIC REVIEW
Banafshei F, Young AH, Juruena MF

I27
A SYSTEMATIC REVIEW OF THE EFFECTS OF CHINESE HERBAL MEDICINES WITH ANTI-INFLAMMATORY EFFECTS IN MOOD DISORDERS
Hou M, Baldwin DS, Hou R
Group J: Other

J01
CAN PERIPHERAL MEASUREMENTS OF BASELINE OXYTOCIN IN SALIVA AND PLASMA PROVIDE RELIABLE BIOMARKERS?
Martins D, Gabay A, Mehta M, Paloyelis

J02
EFFECTS OF POST-LEARNING REM SLEEP DEPRIVATION ON HIPPOCAMPAL ZIF268 AND MIR-124 EXPRESSION IN MICE
Kilic E, Karabulut S, Kilic E, Bayramov KK, Golgeli A

J03
AYAHUASCA BEVERAGE INDUCES CHANGES ON THE EXPRESSION OF GLUTAMATE RECEPTORS IN THE HIPPOCAMPUS OF WISTAR RATS
Gervasio VP, Bertequini RB, Calfi GS, Rosa MLNM

J04
MODULATORS OF GERANYLATION SHOW SELECTIVE TOXICITY ON NF2-NULL CELLS VIA PROMOTING NUCLEAR RAC1 CYTOTOXIC FUNCTION
Zavyalov GA, Stepanova DS, Shimanovskiy NL, Tyulganova DA, Chernoff JC

J05
PREDICTING RESPONSES TO PSYCHEDELICS: A PROSPECTIVE STUDY

J06
INTERGENERATIONAL TRANSMISSION OF PSYCHOPATHOLOGY: FROM ANTENATAL DEPRESSION TO CHILD SYMPTOMS IN THE PRAM-D COHORT.
Sawyer K, Bind RH, Allegri B, Osborne S, Conroy S, Sethna V, Pawlby S, Pariante CM

Susan Chandler 21/06/18